Starling Oncology (STLNW) Tax Provisions (2020 - 2025)

Starling Oncology (STLNW) has reported Tax Provisions for 5 consecutive years, with -$131000.0 the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, Tax Provisions changed N/A year-over-year to -$131000.0; the trailing twelve-month figure through Mar 2026 stood at -$131000.0 (changed N/A YoY), and the FY2025 full-year result was -$131000.0, changed N/A from the prior year.
• Tax Provisions rose to -$131000.0 in Q2 2025 per STLNW's latest filing, from -$314000.0 in the prior quarter.
• Across five years, Tax Provisions topped out at $799000.0 in Q3 2021 and bottomed at -$2.5 million in Q4 2021.
• Historically, Tax Provisions has averaged -$83153.8 across 4 years, with a median of $44000.0 in 2023.
• The widest YoY moves for Tax Provisions: up 6254.89% in 2021, down 388.16% in 2021.
• Over 4 years, Tax Provisions stood at -$2.5 million in 2021, then soared by 85.13% to -$367000.0 in 2022, then gained by 14.44% to -$314000.0 in 2023, then jumped by 58.28% to -$131000.0 in 2025.
• According to Business Quant data, Tax Provisions over the past three periods registered -$131000.0, -$314000.0, and $135000.0 for Q2 2025, Q4 2023, and Q3 2023 respectively.